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INTRODUCTION
There are a few studies about the secretion of gonado-
tropins in women. Acute testosterone infusion to normal
women with and without testolactone inhibits LH sssecre-
tion in a dose-dependent manner, without no effect on FSH
secretion,1 while short-term administration of testosterone
to normal women and eugonadal female-to-male transsex-
uals did not alter either gonadotropin levels, or affect the
pulsatile secretion of LH.2
Regarding the effect of chronic hyperandrogenemia, in
polycystic ovary syndrome a specific pattern of gonado-
tropins secretion has been described, with an increased
concentration of basal LH and diminished FSH and with an
increase in the frequency of LH pulses,3 while in adrenal or
ovarian androgen-secreting tumors, gonadotropin levels
vary from high,4-6 normal for age7-9 or suppressed.7,10-11
The reason for the different gonadotropins pattern in
androgen-secreting tumors is not clear. It is possible that
the level of testosterone and the time exposure could
influence the secretion of gonadotropins, as postulated by
Spinder et al in transsexual2 and Bachelot et al in virilizing
ovarian tumors.10
We report one patient with an adrenal androgen-secreting
tumor (adrenal adenoma), where we document for the first
time the transition of gonadotropin levels from normal to a
suppressed state.
CASE REPORT
A 49-year-old female with a 4-year history of amenorrhea,
excessive hair growth, hair loss, and deepening of the voice
was admitted to the hospital. She had had normal menstrual
cycling since menarche and denied hot flushes. At pre-
sentation she denied using any medication in the previous 6
months.
Physical examination revealed a normal weight (bodymass
index of 22.6 kg/m2), parietal temporal baldness, and marked
hirsutism. Her muscle mass was slightly enlarged. Blood
pressure was 1206 70 mmHg and heart rate was 76 beats/
min. Breasts were hypoatrophic, without masses or galactor-
rhea. The abdomen was normal, and a pelvic examination
revealed clitoromegaly. No anexial mass was palpable.
The initial laboratory investigation revealed a normal
blood count. Liver and renal functions were within normal
range. Basal hormone evaluation revealed an increased level
of total testosterone with a level of DHEAS, estradiol and
gonadotropins concentration normal for age (Table 1).
Dexamethasone suppression test (0.5 mg, q.i.d. for 5 days)
failed to suppress testosterone levels, whereas cortisol and
DHEAS were suppressed normally. Cushing syndrome was
ruled out by an overnight dexamethasone suppression test
(1.0 mg - cortisol , 1.0 mg/dL).
Pelvic ultrasonography showed a right ovary of 6.8 cc and
a left ovary of 5.8 cc, without nodules or cysts. Computed
tomography of the abdomen disclosed a normal right
adrenal gland. A solid nodule of 1.58 cm was seen on the
left adrenal gland.
The patient refused further evaluation at that time, but
appeared for a new evaluation 2 years later. Her physical
examination was largely unchanged, except for progression
of temporal balding. Basal hormone levels of total testoster-
one and estradiol did not change significantly (Table 1),
while basal gonadotropin levels were suppressed in two
separated samples. After acute GnRH administration,
gonadotropin levels remained suppressed.
Pelvic ultrasonography showed a right ovary of 2.7 cc and
a left ovary of 1.8 cc, without nodules or cysts. On
Computed Tomography of the abdomen, the solid nodule
on the left adrenal gland was unchanged.
The patient underwent a left adrenalectomy by laparo-
scopy. The tumor measured 4.564.062.5 cm and weighed
45 g. Macroscopically, the tumor was encapsulated with a
thin, smooth, fibrous capsule. The tumor had a firm
consistency with a variable brown to yellow colour on
cross-section. There were no haemorrhages, necrosis or
cystic degenerations. On microscopical examination, the
tumor consisted of large polygonal cell with abundant
eosinophilic cytoplasm, which showed focal peripherical
basophilic granules and sometimes fine clear, vacuolation.
Occasionally, there was some lipofuchsin pigment.
The patient was submitted to blood collection 6 and 45
days and re-examined 60 days after the surgical procedure.
Total testosterone and estradiol decreased while gonado-
tropins increase to postmenopausal range. She reported hot
flushes and reduced libido, however male pattern baldness
and hirsutism were unchanged.
DISCUSSION
The patient in this case study is a 49-year-old woman with
a history of virilization for four years and an adrenal
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adenoma. Upon first examination, her basal gonadotropin
levels were normal. The patient refused further examination
or treatment, and was not seen in our out-patient clinic for
two years. Upon her return, basal and GnRH-stimulated
gonadotropin levels were suppressed, without significant
change in total testosterone and estradiol levels. After
surgery, gonadotropins increased to postmenopausal range.
As gonadotropin levels in adrenal and ovarian androgen-
secreting tumors have been described as variable,4-11 this
case led us to question whether the time of exposure of the
gonadotrophic axis could be one factor that regulates
gonadotropin levels in virilizing syndrome.
In patients with polycystic ovary syndrome, a state of
chronic mild hyperandrogenemia, dynamic abnormalities of
gonadotropins secretion are some of the most prominent
findings.3 High basal LH levels and increased LH pulse
amplitude have been described and may be related to
elevated oestrogen levels3. This same pattern of abnormality
was also described in a patient with a luteinized thecoma of
the ovary.12
In the other hand, there is not a specific pattern of
gonadotropin levels in patients with virilizing tumors,
except for inhibin-secreting ovarian tumors, where FSH is
suppressed and LH can be normal or low.13 As a rule,
gonadotropin levels in androgen-secreting ovarian tumors
have been described as normal or suppressed.7-11
Additionally, mean basal LH levels and LH pulse number
and amplitude were lower in patients with ovarian tumors
than compared to those with PCOS or normal women,10
suggesting different mechanisms of hypothalamic or pitui-
tary feedback. In the same way, gonadotropin levels in
patients with adrenal androgen-secreting tumors have also
been reported as normal or suppressed, and significantly
lower than in patients with non-tumors forms of hyperan-
drogenism.5
As long-term administration of androgens to women
leads to virilizing effects, some of them irreversible, the
effects of testosterone on gonadotropins secretion in normal
women have been studied in female-to-male transsexual
subjects.2 Administration of testosterone undecanoate for
six-weeks to eugonadal transsexuals, or for three-months to
agonadal transsexuals, did not affect the pulsatile secretion
of LH or the basal levels of LH and FSH, despite the fact that
this regimen resulted in a biologically effective androgen
milieu. On the other hand, testosterone-esters administered
to agonadal female-to-male transsexuals for at least six
months, resulting in higher testosterone levels, were asso-
ciated with a significant decrease in mean basal LH and FSH
levels.2 It is interesting to note that while acute testosterone
infusion inhibited LH secretion in a dose-dependent manner,
without any effect on FSH secretion1, long term administra-
tion was associated with a decrease in both LH and FSH
levels2. According to the authors, this could be a consequence
of the duration of testosterone exposure.
To our knowledge, this is the first documented case of
changing patterns of gonadotropins secretion observed in a
patient with Virilizing Syndrome. This cannot be attributed
to spontaneous fluctuation of gonadotropins secretion
because responses to acute GnRH stimuli were blunted. In
the same way, there was no change in the androgen milieu,
as total testosterone and estradiol levels were unchanged. It
could be that the gonadotropins pattern in virilizing states
changes with time, as in female-to-male transsexuals.2 In
fact, an inhibitory effect of testosterone and dihydrotestos-
terone on the LH response of GnRH in rat pituitary cells has
been reported14. According to this, when the tumor was
removed and the testosterone level felt, there was a gradual
release of the gonadotrophic axis, with increase of the
gonadotropins levels to the status of menopause.
CONCLUSION
We report a patient who showed a changing pattern of
gonadotropin levels that appeared to be time-dependent. As
there were no changes in testosterone and estradiol levels,
we postulate that exposure of the hypothalamus-pituitary to
an androgen milieu over time can regulate gonadotropin
levels in patients with androgen-secreting tumors.
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